NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for patients with neurological disorders, announced its participation in two major industry conferences in December 2025. The company will exhibit at the American Epilepsy Society (AES) 2025 Annual Meeting in Atlanta, GA, from December 5th to December 9th, and the CNS Drug Delivery Summit in Boston, MA, from December 9th to 11th.
The AES Annual Meeting, as detailed on the AES Annual Meeting Registration page, brings together healthcare providers, scientists, advocates, and industry professionals dedicated to improving outcomes for people with epilepsy. This conference provides a platform for NeuroOne to engage with key stakeholders and highlight its advancements in EEG recording, monitoring, and ablation technologies.
Following the AES meeting, NeuroOne will attend the CNS Drug Delivery Conference, which convenes over 100 industry experts, including neuroscientists, chemists, device engineers, and delivery specialists. The summit focuses on cutting-edge strategies to overcome challenges in accessing the brain for therapeutic delivery. NeuroOne's participation underscores its commitment to developing solutions for drug delivery and stimulation in neurological disorders such as Parkinson's disease, essential tremors, and chronic pain.
Dave Rosa, CEO of NeuroOne, stated, 'Our involvement in these conferences reflects our dedication to advancing minimally invasive, hi-definition solutions that improve patient outcomes and reduce procedural costs. We look forward to collaborating with peers and showcasing our technologies.'
NeuroOne's product pipeline includes solutions for epilepsy, movement disorders, and chronic pain, with potential applications in depression, mood disorders, and artificial intelligence. The company's participation in these events is critical for networking, sharing clinical data, and exploring partnerships that could accelerate the adoption of its technologies.
The conferences come at a pivotal time for the neuromodulation market, as demand grows for less invasive surgical options. NeuroOne's focus on high-definition EEG recording and targeted ablation aligns with trends toward precision medicine in neurology. By engaging with leading experts, the company aims to solidify its position as a key player in the evolving landscape of neurological care.
